Lemaire Sandrine, Van Bambeke Françoise, Mingeot-Leclercq Marie-Paule, Tulkens Paul M
Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, Mounier 73, Brussels, Belgium.
Antimicrob Agents Chemother. 2007 Aug;51(8):2748-57. doi: 10.1128/AAC.00090-07. Epub 2007 Jun 4.
P-glycoprotein (P-gp; MDR1), a major efflux transporter, recognizes various antibiotics and is present in macrophages. We have examined its effect on the modulation of the intracellular accumulation and activity of daptomycin towards phagocytized Staphylococcus aureus (ATCC 25923) in human THP-1 macrophages, in comparison with MDCK epithelial cells (wild type and MDCK-MDR1 overexpressing P-gp; the bulk of the protein was immunodetected at the surface of all three cell types). Daptomycin displayed concentration-dependent intracellular activity (Hill equation pattern) in THP-1 and MDCK cells with (i) 50% effective drug extracellular concentration (EC(50); relative potency) and static concentrations at 9 to 10 times the MIC and (ii) maximal efficacy (E(max); CFU decrease at infinite extracellular drug concentration) at 1.6 to 2 log compared to that of the postphagocytosis inoculum. Verapamil (100 microM) and elacridar (GF 120918; 0.5 microM), two known inhibitors of P-gp, decreased daptomycin EC(50) (about threefold) in THP-1 and MDCK cells without affecting E(max). Daptomycin EC(50) was about three- to fourfold higher and accumulation in MDCK-MDR1 commensurately lower than in wild-type cells. In THP-1 macrophages, (i) verapamil and ATP depletion increased, and ouabain (an inducer of mdr1 [the gene encoding P-gp] expression) decreased the accumulation of daptomycin in parallel with that of DiOC(2) (a known substrate of P-gp); (ii) silencing mdr1 with duplex human mdr1 siRNAs reduced the cell content in immunoreactive P-gp to 15 to 30% of controls and caused an eight- to 13-fold increase in daptomycin accumulation. We conclude that daptomycin is subject to efflux from THP-1 macrophages and MDCK cells by P-gp, which reduces its intracellular activity against phagocytized S. aureus.
P-糖蛋白(P-gp;多药耐药蛋白1)是一种主要的外排转运蛋白,可识别多种抗生素,且存在于巨噬细胞中。我们研究了其对达托霉素在人THP-1巨噬细胞中针对吞噬的金黄色葡萄球菌(ATCC 25923)的细胞内蓄积及活性调节的影响,并与MDCK上皮细胞(野生型和过表达P-gp的MDCK-MDR1;在所有三种细胞类型的表面均能免疫检测到大量该蛋白)进行了比较。达托霉素在THP-1和MDCK细胞中呈现浓度依赖性细胞内活性(希尔方程模式),(i)50%有效药物细胞外浓度(EC50;相对效价)以及静态浓度为最低抑菌浓度的9至10倍,(ii)与吞噬后接种物相比,在细胞外药物浓度无限时最大效应(E(max);菌落形成单位减少)为1.6至2个对数。维拉帕米(100 microM)和艾拉莫德(GF 120918;0.5 microM)这两种已知的P-gp抑制剂,可降低THP-1和MDCK细胞中达托霉素的EC50(约三倍),而不影响E(max)。达托霉素在MDCK-MDR1中的EC50比野生型细胞高约三至四倍,其蓄积量相应较低。在THP-1巨噬细胞中,(i)维拉帕米和ATP耗竭会增加,而哇巴因(一种mdr1[编码P-gp的基因]表达诱导剂)会降低达托霉素的蓄积,这与DiOC(2)(一种已知的P-gp底物)的蓄积情况平行;(ii)用双链人mdr1 siRNAs沉默mdr1可使免疫反应性P-gp的细胞含量降至对照的15%至30%,并使达托霉素的蓄积增加八至十三倍。我们得出结论,达托霉素会被P-gp从THP-1巨噬细胞和MDCK细胞中外排,这会降低其对吞噬的金黄色葡萄球菌的细胞内活性。